Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
Determinants of Outcome in Diffuse Parenchymal Lung Disease
The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.
It is well known that both socioeconomic and biological factors may contribute to race- and ethnicity-based health disparities. Black and Hispanic Americans have worse access to healthcare services and tend to receive care from physicians who cannot themselves access the same services for their patients that physicians who care for white patients can. These factors may play important roles in the development and maintenance of health disparities. In addition, biological differences may contribute to disparities. We propose to identify factors that explain survival disparities in a group of lung diseases called diffuse parenchymal lung diseases (DPLDs), including a severe form of DPLD called idiopathic pulmonary fibrosis (IPF). We will follow patients with DPLD at our center and measure both social and biological factors to try to identify the factors that lead to survival disparities between races. Results of this study will be used to design clinical trials aimed at reducing these disparities. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
| Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
| Not yet recruiting |
NCT06241560 -
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
|
Phase 2 | |
| Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
| Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
| Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
| Not yet recruiting |
NCT06422884 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
|
Phase 2 | |
| Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
| Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
| Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
| Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
| Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
| Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 |